Vector

The finding exposes the danger of older, unpatched bugs, which plague at least 4.5 million devices.

"While this allows organizations to focus on their core business logic and release code faster, this also introduces a security risk in the form of software vulnerabilities," he says. "Once you are aware of the risk, make sure you have the right processes and tools in place that will allow you to effectively take action," he says. "First, many organizations with less mature security programs do not even have visibility into the vulnerabilities they have in their environment," he says. Externally accessible vulnerabilities expected to remain a favorite attack vector for cybercriminals in the future. It is unknown how many of the more than 167,000 applications using this library are running vulnerable versions, according to Vicarius, which published a report detailing the attack path. The tool is used by thousands of Google services, but prior to a September 2021 patch, it housed unsafe and exploitable functions, potentially exposing user input data.

... -- Transformational precision gene delivery company launched out of Versant's Ridgeline Discovery Engine –. -- Vector developing platform for precisely ...

Vector is located in Basel, Switzerland and has a 40-member staff that is expected to increase as the company expands its platform and pipeline of therapeutic candidates. Incorporating cutting-edge platform technologies, from world-class academic research at the University of Zürich, Vector BioPharma uses engineered virus-like particles to achieve cell- and tissue-specific delivery and tunable expression of genes and regulators with unprecedented precision. “We’re thrilled to be working with Lorenz, Andreas and the team to advance Vector’s rationally designed gene delivery technology,” said Alex Mayweg, Ph.D., Managing Director at Versant and a Vector board member. Since the firm’s founding in 1999, more than 85 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com. The company is backed by Versant Ventures. For more information, please visit www.vectorbiopharma.com. Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. BASEL, Switzerland--( BUSINESS WIRE)-- Versant Ventures today announced the debut of Vector BioPharma AG, a biopharmaceutical company developing a precision gene delivery platform that is devoid of viral genes. In the first half of 2023, Vector expects to have in vivo data for its lead pipeline programs. This compares favorably with conventional viral gene delivery technologies such as AAV that are only capable of packaging 4.7 kb. Lorenz Mayr, Ph.D., CEO. Dr. Mayr is an experienced executive from Bayer, Novartis, AstraZeneca and GE Healthcare, where he led a 2,000 member-strong R&D organization. The platform combines high-capacity virus-like particles with designed, exogenous, high-avidity adapter proteins. Finally, the viral capsid is engineered and shielded from the immune system, providing a safe and stable delivery system that carries complex and multiple gene cassettes with a large genome packaging capacity of up to 36 kb.

Milvus is one of the world's most advanced vector databases, capable of managing massive quantities of both structured and unstructured data to accelerate the ...

Vector BioPharma AG, a biopharmaceutical company developing a precision gene delivery platform devoid of viral genes, has launched with a $30 million Series ...

In the first half of 2023, Vector says it expects to have in vivo data for its lead pipeline programs. Versant Ventures has announced the debut of Vector BioPharma AG, a biopharmaceutical company developing a precision gene delivery platform devoid of viral genes. Vector is located in Basel, Switzerland and has a 40-member staff that is expected to increase as the company expands its platform and pipeline of therapeutic candidates. Because of their drawbacks, there has been strong interest in alternatives to adeno-associated viral (AAV) vectors, such as modified transgenes and a cytomegalovirus-based vector. “We’re thrilled to be working with Lorenz, Andreas and the team to advance Vector’s rationally designed gene delivery technology,” said Alex Mayweg, PhD, Managing Director at Versant and a Vector board member. This compares favorably with conventional viral gene delivery technologies such as AAV that are only capable of packaging 4.7 kb.

Versant Ventures today announced the debut of Vector BioPharma AG, a biopharmaceutical company developing a precision gene delivery platform that is d.

Vector is located in Basel, Switzerland and has a 40-member staff that is expected to increase as the company expands its platform and pipeline of therapeutic candidates. Incorporating cutting-edge platform technologies, from world-class academic research at the University of Zürich, Vector BioPharma uses engineered virus-like particles to achieve cell- and tissue-specific delivery and tunable expression of genes and regulators with unprecedented precision. Since the firm’s founding in 1999, more than 85 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit www.versantventures.com. Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The company is backed by Versant Ventures. For more information, please visit www.vectorbiopharma.com. “We’re thrilled to be working with Lorenz, Andreas and the team to advance Vector’s rationally designed gene delivery technology,” said Alex Mayweg, Ph.D., Managing Director at Versant and a Vector board member. BASEL, Switzerland--( BUSINESS WIRE)--Versant Ventures today announced the debut of Vector BioPharma AG, a biopharmaceutical company developing a precision gene delivery platform that is devoid of viral genes. In the first half of 2023, Vector expects to have in vivo data for its lead pipeline programs. Lorenz Mayr, Ph.D., CEO. Dr. Mayr is an experienced executive from Bayer, Novartis, AstraZeneca and GE Healthcare, where he led a 2,000 member-strong R&D organization. This compares favorably with conventional viral gene delivery technologies such as AAV that are only capable of packaging 4.7 kb. The platform combines high-capacity virus-like particles with designed, exogenous, high-avidity adapter proteins. Finally, the viral capsid is engineered and shielded from the immune system, providing a safe and stable delivery system that carries complex and multiple gene cassettes with a large genome packaging capacity of up to 36 kb.

Most of the gene therapy world centers around viral vectors, but a few biotechs have sprung up in recent years to try and avoid the safety issues that can ...

Vector’s 40-employee team will have technical proof-of-concept data in immuno-oncology and genome editing this year, the company said. The non-viral route has spurred a few new biotechs in recent years. Can you do it?’” the Versant managing director said. Amid a broader biotech bear market, gene therapy startups have been particularly affected, as cash crunches have led to multiple rounds of layoffs. The enhanced payload capacity could attract pharma partners, Mayweg said. “We can do dystrophin or others that are really massive, and that’s no problem.